¿ Cerep SA, of Paris, reported revenues of EUR4.6 million (US$4.05 million) for the third quarter, exactly double its turnover in the corresponding three months of 1999. The main boost to the drug discovery company's revenues came from research collaborations, income that tripled to EUR1.8 million from EUR600,000 in the third quarter of 1999. For the first nine months of 2000, Cerep's turnover was up 84 percent at EUR 12.6 million, compared with EUR6.9 million in the same period last year, with research and development funding from third parties accounting for EUR5.2 million (41.3 percent) of the total, up from EUR1.7 million (24.6 percent) the year before.

No Comments